Melanie Senior on Muck Rack

Melanie Senior

London, UK
Freelance Biopharma Writer and Analyst — Freelance

Biopharma writer (Nature Bio, IN VIVO, EY Life Sci.); runner & twitter schizo

Search Tweets

Twitter Feed

@RealEndptsMel — 621 followers, 242 tweets

More senior, C-suite pharma execs should be present at the closest thing to a public pricing debate in the US for most significant new drug class since biologicals 
@reutersBenHir Peak sales of $400m IF it's approved? Ultra-rare disorder = high price = payer pushback. Novo got it right this time - but not for ignoring BD for the last decade. Another hoped-for "major EU biotech" bites the dust. Still, valuable dust for the lucky shareholders..
We are clever enough to analyse, select, edit and re-infuse genes to cure blindness. But we struggle to find a practicable payment structure to link vision to $$. Or health to $$, for that matter.  NVS ambition to pioneer EU gene therapy pricing model? Good. But hard to see $$ return near-term - $170m (deal tag) represents about 200 patients, at current Luxturna price. Might be more like 500 at EU price. Find them!
Show More